- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT07645222
PHASE 1b STUDY OF HS-20122 COMBINED THERAPY IN NSCLC
A PHASE Ib STUDY OF THE SAFETY, EFFICACY, PHARMACOKINETICS, AND IMMUNOGENICITY OF HS-20122 COMBINED THERAPY IN ADVANCED NON-SMALL CELL LUNG CANCER PATIENTS
Studie Overzicht
Toestand
Conditie
Gedetailleerde beschrijving
Studietype
Inschrijving (Geschat)
Fase
- Fase 1
Contacten en locaties
Studie Locaties
-
-
Guangdong
-
Guangzhou, Guangdong, China
- Werving
- Ethics Committee of Sun Yat-sen University Cancer Center
-
Contact:
- Ran Xu, MD
- Telefoonnummer: 86-20-87343009
- E-mail: llwyh@sysucc.org.cn
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
- Volwassen
- Oudere volwassene
Accepteert gezonde vrijwilligers
Beschrijving
Inclusion Criteria:
- Locally advanced or metastastic NSCLC;
- Received at least 1 line SoC,or treatment naïve;
- With at least 1 target lesion according to RECIST 1.1.
- Appropriate organ function
- Eastern Cooperative Oncology Group (ECOG) performance status (PS) score of 0-1 and no deterioration within 2 weeks prior to the first dose.
- Minimum expected survival longer than 12 weeks
- Female subjects of childbearing potential are willing to take appropriate contraceptive measures and should not breastfeed from signing the informed consent form (ICF) through 6 months after the last dose; male subjects are willing to use barrier contraception (i.e., condom) from signing the ICF through 6 months after the last dose.
- Voluntarily participate in this clinical trial, understand the study procedures, and be able to sign written informed consent form.
Exclusion Criteria:
- Insufficient wash out duration of prior systemic anticancer therapy
- Local radiotherapy within 2 weeks prior to first dose of investigational drug
- Pleural/abdominal effusion requires clinical intervention
- Major surgery within 4 weeks prior to first dose of investigational drug
- History of drugs may prolong QT interval
- Have any grade ≥ 2 residual toxicity according to Common Terminology Criteria for Adverse Events (CTCAE, version 5.0) from prior anti-tumor therapy (except alopecia and residual neurotoxicity).
- Presence of brain metastasis or carcinomatous meningtitis
- History of other primary malignancies
- Significant, uncontrolled, or active cardiovascular diseases
- Severe or poorly controlled diabetes
- Extremely obesity or emaciation
- Clinically significant bleeding symptoms or obvious bleeding tendency within 1 month prior to the first dose
- Severe arteriovenous thrombotic events (e.g., deep venous thrombosis, pulmonary embolism) within 3 months prior to the first dose
- Severe infection within 4 weeks
- History of systemic glucocorticoids over 28 days prior to first dose of investigational drug
- Presence of known active infectious diseases,
- Prensence of ophthalmological abnormalities.
17.Presence of hepatic encephalopathy, Hepato-renal Syndrome 18.Presence or history of confirmed or suspected ILD; 19.Prior history of significant neurological or mental disorders, including conditions that interfere with assessment, such as epilepsy, dementia, or major depressive disorder.
20.History of severe allergy, or history of hypersensitivity to any active or inactive ingredient of investigational drugs.
21.Presence of any conditions that jeopardize subject safety or interfere with study assessments as judged by the investigator.
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Niet-gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: HS-20122+Aumolertinib
|
EGFR mut NSCLC, receive HS-20122+Aumolertinib
|
|
Experimenteel: HS-20122+Adbrelimab
|
EGFRwt NSCLC,receive HS-20122+Adbrelimab
|
|
Experimenteel: HS-20122+Adbrelimab+Platinum-based Chemo
|
EGFR wt NSCLC,receive HS-20122+Adbrelimab+ Platinum-based Chemo
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
SAE
Tijdsspanne: Gedurende de volledige duur van deze trial, ongeveer 2 jaar
|
incidentie van door de onderzoeker geëvalueerde Ernstige Bijwerkingen, gegradeerd volgens CTCAE V5.0
|
Gedurende de volledige duur van deze trial, ongeveer 2 jaar
|
|
RP2D for Combination
Tijdsspanne: Through the full duration of this trial, approximately 2 years
|
To evaluate the potent and tolerated of combination(s) and dosage(s) of HS-20122 based therapy in subjects with locally advanced or metastatic NSCLC who have experienced disease progression on or after prior treatment, which suitable for a Phase II trial
|
Through the full duration of this trial, approximately 2 years
|
|
ORR
Tijdsspanne: Through the full duration of this trial, approximately 2 years;
|
Investigator evaluated overall response rate, to evaluate the efficacy of each combination;
|
Through the full duration of this trial, approximately 2 years;
|
|
TEAE
Tijdsspanne: Through the full duration of this trial, approximately 2 years;
|
incidence of Investigator evaluated Treatment Emerged Adverse Events, graded per CTCAE V5.0
|
Through the full duration of this trial, approximately 2 years;
|
|
TRAE
Tijdsspanne: Through the full duration of this trial, approximately 2 years;
|
incidence of Investigator evaluated Treatment Related Adverse Events, graded per CTCAE V5.0
|
Through the full duration of this trial, approximately 2 years;
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Duration of Response
Tijdsspanne: Through the full duration of this trial ,approximately 2 years
|
Investigator evaluated Duration of Response
|
Through the full duration of this trial ,approximately 2 years
|
|
Disease Control Rate
Tijdsspanne: Through the full duration of this trial ,approximately 2 years;
|
Investigator evaluated Disease Control Rate
|
Through the full duration of this trial ,approximately 2 years;
|
|
Progression Free Survival
Tijdsspanne: Through the full duration of this trial, approximately 2 years;
|
Investigator evaluated duration of Progression Free Survival
|
Through the full duration of this trial, approximately 2 years;
|
|
Overall Survival
Tijdsspanne: Through the full duration of this trial ,approximately 2 years;
|
Investigator evaluated duration of Overall Survival
|
Through the full duration of this trial ,approximately 2 years;
|
|
PK parameter
Tijdsspanne: Through the full duration of this trial, approximately 2 years;
|
blood concentration of combo agents
|
Through the full duration of this trial, approximately 2 years;
|
|
Immuogencity
Tijdsspanne: Through the full duration of this trial ,approximately 2 years;
|
positive rate of drug specific antibody
|
Through the full duration of this trial ,approximately 2 years;
|
Medewerkers en onderzoekers
Sponsor
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- HS-20122-103
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .